Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790146 | 0.82 | NISCH (0.41) | SIGMAR1HTR2CNISCH | |
| SCHEMBL4790187 | 0.81 | CHRNB2 (0.38) | NISCHRAB9A | |
| SCHEMBL4790395 | 0.81 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR7 | |
| SCHEMBL4789908 | 0.81 | PTGS1 (0.34) | SIGMAR1HTR7 | |
| SCHEMBL578563 | 0.81 | HTR2C (0.50) | SIGMAR1HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL7367385 | 0.80 | SIGMAR1 (0.47) | SIGMAR1HTR2CF2HTR6HTR2A | |
| SCHEMBL4790156 | 0.79 | NISCH (0.37) | HTR2CNISCHHTR7 | |
| SCHEMBL4790265 | 0.79 | HTR2C (0.54) | HTR2C | |
| SCHEMBL4789903 | 0.79 | ADRA2A (0.41) | HTR2C | |
| SCHEMBL5120309 | 0.79 | CYP11B1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 833 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000003713-A1 | TREATMENT FOR SCHIZOPHRENIA AND OTHER DOPAMINE SYSTEM DYSFUNCTIONS | NELSON JODI A (US) | 2000-01-27 | — | — | WO | claimed |
| WO-2025042769-A1 | COMPOUNDS AND METHODS FOR INHIBITING POLY(ADP-RIBOSE) POLYMERASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240415973-A1 | USES OF HYALURONAN CONJUGATES | AIHOL CORPORATION (US) | 2024-12-19 | — | — | US | disclosed |
| US-12128108-B2 | Hyaluronan conjugates and uses thereof | AIHOL CORPORATION (US) | 2024-10-29 | — | — | US | disclosed |
| CN-118660868-A | Calcium channel blockers and methods of screening | 解明岐 | 2024-09-17 | — | — | CN | disclosed |
| CN-113660933-B | Hyaluronic acid complexes and uses thereof | 爱禾公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023121740-A1 | IMMUNOREGULATORY COMPOUNDS | NIMML INSTITUTE (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203499-A1 | SYSTEMS AND METHODS FOR TREATING LEVODOPA DYSKINESIA, ENHANCING MOTOR BENEFIT, AND DELAYING DISEASE PROGRESSION | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20230080473-A1 | HYALURONAN CONJUGATES AND USES THEREOF | AIHOL CORPORATION (US) | 2023-03-16 | — | — | US | disclosed |
| EP-2874692-B1 | NON-REGULAR ELECTRICAL STIMULATION PATTERNS FOR IMPROVED EFFICIENCY IN TREATING PARKINSON'S DISEASE | UNIV DUKE (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-1999004775-A9 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY INC (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0819002-A1 | USE OF IMIDAZOL 1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | Clarendon-Trading & Investimentos LDA (PT) | 1998-01-21 | — | — | EP | disclosed |
| EP-0440777-B1 | BRAIN DERIVED NEUROTROPHIC FACTOR | MAX PLANCK GESELLSCHAFT (DE) | 1997-02-12 | — | — | EP | disclosed |
| EP-0749311-A1 | PHARMACEUTICAL COMPOSITION OF INDENE DERIVATIVES FOR REGULATING APOPTOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996031210-A1 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996021445-A1 | METHODS OF INHIBITING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996021449-A1 | PHARMACEUTICAL COMPOSITION OF INDENE DERIVATIVES FOR REGULATING APOPTOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996014397-A9 | PORCINE CORTICAL CELLS AND THEIR USE IN TREATMENT OF NEUROLOGICAL DEFICITS DUE TO NEURODEGENERATIVE DISEASES | — | 1996-06-27 | — | — | WO | disclosed |
| WO-1996005319-A1 | GENETICALLY ENGINEERED CELLS THAT PRODUCE DOPAMINE | ARCH DEVELOPMENT CORPORATION (US) | 1996-02-22 | — | — | WO | disclosed |
| WO-1992015298-A2 | PYRAZOLE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL ULCER DISEASE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230080473-A1 | HYALURONAN CONJUGATES AND USES THEREOF | CD44, SHBG, HTT | SIGMAR1 3541/4885HTR2C 1831/4885NISCH 1342/4885 |
| US-20240415973-A1 | USES OF HYALURONAN CONJUGATES | CD44, SHBG, HTT | SIGMAR1 3427/4885HTR2C 1851/4885NISCH 1524/4885 |
| US-12128108-B2 | Hyaluronan conjugates and uses thereof | CD44, SHBG, HTT | SIGMAR1 3541/4885HTR2C 1831/4885NISCH 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.